PRESS RELEASE: MHRA Award Accreditation for MAC's Phase 1 Site
MAC Neuroscience Centre of excellence, the early phase division of MAC Clinical Research, has been awarded Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA) MANCHESTER, ENGLAND – October 17, 2016 – MAC Clinical Research (MAC) today announced it has been awarded MHRA accreditation for Phase 1 clinical trials located at its Citylabs facility within the Manchester Royal Infirmary Campus (MRI). With a strong team, MAC will continue to conduct a full range of phase 1 clinical trials with a focus on early phase patient studies.
MAC, with its well established UK network of later phase clinics, has a long history and successful track record in recruiting various patient groups into Clinical Trials. The new Early Phase Unit (EPU) is ideally placed for First-in-Human and First-in-Patient trials as well as the increasing number of “umbrella” protocols appearing in Early Phase Research.
“The UK remains the best place to undertake Phase 1 research” commented CEO Dr Mark Dale “and we are pleased to add a new commercial unit to the list of those accredited by the MHRA. Our expert team led by Charlotte Chadwick and Peter Dewland has a relentless commitment to continually improving safety and quality and our MHRA Accreditation provides volunteers and sponsors with additional reassurance of the high standards at MAC in performing clinical studies.”
Source: MAC Clinical Research
Further information: www.macplc.com